Granted Patent
B2
US 12,304,970 · App. 16/967,110 · Granted May 20, 2025
Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
Assignee:
YALE UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Amino acid sequences capable of enhancing nuclear translocation are provided. Also referred to a nuclear localization signals (NLS) the sequences can be linked to or grafted into antibodies or fragments or fusion proteins thereof to enhance nuclear translocation of the antibody. Compositions and antibodies including an NLS conjugated or otherwise linked directly or indirectly to an active agent cargo are also provided. Exemplary cargo includes proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, inorganic molecules, organic molecules, and diagnostic agents. Pharmaceutical compositions further including a pharmaceutically acceptable carrier are also provided. Methods of delivering the composition or antibody alone or with a cargo linked thereto to the nucleus of cell, methods of selecting or screening for compositions having a desired cellular activity, and methods of treating diseases and disorders are also provided.
Claims (7)
1. A composition comprising a nuclear localization signal (NLS) comprising the amino acid sequence any one of SEQ ID NOS: 50-52, wherein the NLS can translocate from the cytoplasm to the nucleus of a cell, wherein the composition does not consist of an antibody comprising an amino acid sequence 100% identical to SEQ ID NOS: 1, 2, 22, 23, 42, 54, 55, and 56.
2. The composition of claim 1 wherein the NLS consists of the amino acid sequence of any one of SEQ ID NOS: 50-52.
3. The composition of claim 1 further comprising an active agent cargo linked directly or indirectly to the NLS.
4. The composition of claim 3 , wherein the cargo is selected from the group consisting of proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, inorganic molecules, and organic molecules, and diagnostic agents.
5. A composition comprising a pharmaceutically acceptable carrier and the composition of claim 1 .
6. The composition of claim 5 , further comprising a therapeutic agent.
7. A method of delivering a composition to the nucleus of a cell comprising contacting the cell with the composition of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 24, 2020
From: HANSEN, JAMES E.; RATTRAY, ZAHRA
To: YALE UNIVERSITY
Reel/Frame 053571/0018 →
Continuity (2)
Provisional Application
62625198
· Feb 1, 2018
References Cited (117)
US 4569789A
· Blattler
· 1986
[cited by applicant]
US 4952394A
· Senter
· 1990
[cited by applicant]
US 5137877A
· Kaneko
· 1992
[cited by applicant]
US 5349066A
· Kaneko
· 1994
[cited by applicant]
US 5618528A
· Cooper
· 1997
[cited by applicant]
US 20130225611A1
· Weis
· 2013
[cited by applicant]
EP 3173428
· 2017
[cited by applicant]
WO 1997032602
· 1997
[cited by applicant]
WO 2008091911
· 2008
[cited by applicant]
WO 2010056043
· 2010
[cited by applicant]
WO 2011041721
· 2011
[cited by applicant]
WO 2012135831
· 2012
[cited by applicant]
WO 2012150543
· 2012
[cited by applicant]
WO 2014130723
· 2014
[cited by applicant]
WO 2016020892
· 2016
[cited by applicant]
WO 2016033321
· 2016
[cited by applicant]
WO 2019018426
· 2019
[cited by applicant]
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
[cited by examiner]
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491…
[cited by examiner]
Achuthan, et al., “Drug-induced Senescence Generates Chemoresistant Stemlike Cells with Low Reactive OxygenSpecies”, J. Biol. Chem., 286(43):37813-37829 (2011).
[cited by applicant]
Adams, et al., “Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv1”, Cancer Res., 53:4026-4034 (1993).
[cited by applicant]
Alarcon-Segovia, et al., “Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus”, Clin Exp Immun…
[cited by applicant]
Ambrus, et al., “Small molecule peptidomimetic inhibitors of importin a/b mediated nuclear transport”, Bioorganic & Medicinal Chemistry, 18:7611-7620 (2010).
[cited by applicant]
Axup, et al., “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids”, PNAS, 109(40): 16101-6 (2012).
[cited by applicant]
Bachor, et al., “New method of peptide cleavage based on Edman degradation”, Molecular diversity, 17 (3): 605-11 (2013).
[cited by applicant]
Boswell-Casteel, et al., “Equilibrative nucleoside transporters—A review”, Nucleosides Nucleotide Nucleic Acids, 36(1):7-30 (2017).
[cited by applicant]
Cansizsoglu, et al., “Structure-based design of a pathway-specific nuclear import inhibitor”, Nat. Struct. Mol. Biol., 14(5):452-454 (2007).
[cited by applicant]
Choi, et al., “A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells”, MABS, 6(6):1402-1414 (2017).
[cited by applicant]
Chook, et al., “Nuclear import by Karyopherin-Bs: recognition and inhibition”, Biochim. Biophys. Acta., 1813(9):1593-1606 (2011).
[cited by applicant]
Chothia, et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins” J. Mol. Biol., 196:901-917 (1987).
[cited by applicant]
Deng, et al., “In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies”, Int Immunol., 12(4):415-423 (2000).
[cited by applicant]
Fahrenkrog, et al., “The nuclear pore complex: Nucleocytoplasmic transport and beyond”, Nature Reviews Molecular Cell Biology, 4:757 (2003).
[cited by applicant]
Freitas, et al., “Mechanisms and Signals for the Nuclear Import of Proteins”, Current Genomics, 10(8):550-557 (2009).
[cited by applicant]
Genbank AF289183.1 “Mus musculus anti-DNA monoclonal autoantibody G1-5 light chain variable region mRNA, partial cds”, accessed Apr. 20, 2022.
[cited by applicant]
GenBank: AAA65681.1, “immunoglobulin light chain, partial [Mus musculus]”, accessed Apr. 20, 2022.
[cited by applicant]
GenBank: L16981.1, “Mouse Ig rearranged L-chain gene, partial eds”, Accessed Apr. 20, 2022.
[cited by applicant]
Golan, et al., “Penetration of autoantibodies into living epithelial cells”, J Invest Dermatol 100(3):316-322 (1993).
[cited by applicant]
Gruber, et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in
[cited by applicant]
Gu, et al., “Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-Ipr/Ipr mouse model of systemic lupus erythematosus”, J. Immunol., 161:6999-7006 (1998)).
[cited by applicant]
Hansen, et al. “Antibody-mediated Hsp70 protein therapy”, Brain Res., 1088(1): 187-96 (2006).
[cited by applicant]
Hansen, et al., “Antibody-mediated p53 protein therapy prevents liver metastasis in vivo”, Cancer Res, 67(4): 1769-74 (2007b).
[cited by applicant]
Hansen, et al., “Intranuclear protein transduction through a nucleoside salvage pathway”, J Biol Chem, 282(29):20790-20793 (2007a).
[cited by applicant]
Hansen, et al., “Targeting cancer with a lupus autoantibody”, Sci Transl Med., 4(157):157ra142 (2012).
[cited by applicant]
Hintersteiner, et al., “Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries”, ACS Chem. Biol., 5(10):967979 (2010…
[cited by applicant]
Hu, et al., “Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts”, Cancer Res., 56(13):3055-3061 (1996).
[cited by applicant]
Im, et al., “Cell and nuclear penetrating anti-ds DNA autoantibodies have multiple arginines in CDR3 of VH and increase cellular level of pERK and Bcl2 in mesangial cells”, Mol Immunol., 67:377-387 (2015).
[cited by applicant]
Im, et al., “Development of single-chain Fv of antibody to DNA as intracellular delivery vehicle”, Animal Cells and Systems, 21(6):382-387 (2017).
[cited by applicant]
International Search Report for PCT/US2019/016296 dated May 13, 2019.
[cited by applicant]
Isenberg, et al., “Detection of Cross-Reactive Anti-DNA Antibody Idiotypes in the Serum of Systemic Lupus Erythematosus Patients and of Their Relatives”, Arthritis Rheum 28(9):999-1007 (1985).
[cited by applicant]
Jacobson, et al., “An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-Ipr/Ipr mouse exhibits limited intraclonal affinity maturation”, The Journal of Immunology, 152(9):4489-4499 (19…
[cited by applicant]
Jang, et al., “A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity”, Cell Mol Life Sci, 66(11-12):1985-97 (2009).
[cited by applicant]
Kim, et al., “Heavy and Light Chain Variable Single Domains of an Anti-DNA Binding Antibody Hydrolyze Both Double-and Single-stranded DNAs without Sequence Specificity”, J Biol Chem., 281(22):15287-95 (2006).
[cited by applicant]
Kolodych, et al., “CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability”, Bioconjugate Chem., 26(2): 197-200 (2015).
[cited by applicant]
Kostelny, et al., “Formation of a bispecific antibody by the use of leucine zippers”, J. Immunol., 148(5):1547 (1992).
[cited by applicant]
Kosugi, et al., “Design of Peptide Inhibitors for the Importin a/b Nuclear Import Pathway by Activity-Based Profiling”, Chemistry & Biology, 15:940-949 (2008).
[cited by applicant]
Kosugi, et al., “Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs”, PNAS, 106(25): 10171-10176 (2009).
[cited by applicant]
Lee, et al., “Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA”, Biorg Med Chem., 15:2016-23 (2007).
[cited by applicant]
Lundberg, et al., “Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication”, Antiviral Res, 100(3):662-672 (2013).
[cited by applicant]
Lyon, et al., “Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates”, Bioconjugate Chem., 32(10): 1059-1062 (2014).
[cited by applicant]
McCartney, et al., “Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and b…
[cited by applicant]
Noble, et al., “A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells”, Sci Rep., 4:5958 (2014).
[cited by applicant]
Noble, et al., “DNA-damaging autoantibodies and cancer: the lupus butterfly theory”, Nat. Rev. Rheumatol., 12(7):429-43 (2016).
[cited by applicant]
Noble, et al., “Optimizing a lupus autoantibody for targeted cancer therapy”, Cancer Research, 75(11):2285-2291 (2015).
[cited by applicant]
Pack, et al., “Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in
[cited by applicant]
Rahman, et al., “Systemic lupus erythematosus”, N Engl J Med., 358(9):929-939 (2008).
[cited by applicant]
Rattray, et al., “Re-Engineering and Evaluation of Anti-DNA Autoantibody 3E10 for Therapeutic Applications ”, Biochem Biophys Res Commun, 496: 858-864 (2018).
[cited by applicant]
Rhodes, et al., “TRIM21 and the Function of Antibodies inside Cells”, Trends Immunol., 38(12):916-926 (2017).
[cited by applicant]
Sliwinska, et al., “Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells”, Mech. Ageing Dev., 130(1-2):24-32 (2009).
[cited by applicant]
Soderholm et al., “Importazole, a small molecule inhibitor of the transport receptor importin-β”, ACS Chem Biol 6(7):700-708 (2011).
[cited by applicant]
Spertini, et al., “Idiotypic Vaccination with a Murine Anti-dsDNA Antibody: Phase I Study in Patients with Nonactive Systemic Lupus Erythematosus with nephritis”, J. Rheumatol., 26(12): 2602-8 (1999).
[cited by applicant]
Te Poele, et al., “DNA damage is able to induce senescence in tumor cells in vitro and in vivo”, Cancer Res., 62(6):1876-1883 (2002).
[cited by applicant]
Turchick, et al., “A cell-penetrating antibody inhibits human RAD51 via direct binding”, Nucleic Acids Research, 45(20):11782-11799 (2017).
[cited by applicant]
Van Der Watt, et al., “Targeting the Nuclear Import Receptor Kpnb1as an Anticancer Therapeutic”, Mol Cancer Ther, 15(4):560-573 (2016).
[cited by applicant]
Wagstaff, et al., “An AlphaScreen®-Based Assay for High-throughput Screening for Specific Inhibitors of nuclear Import”, J Biomol Screen, 16(2): 192-200 (2011).
[cited by applicant]
Wagstaff, et al., “Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus”, Biochemical Journal, 443(3): 851-856 (2012).
[cited by applicant]
Wang, et al., “Dipyridamole analogues as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equili…
[cited by applicant]
Wang, et al., “Nuclear import inhibitor N-(4-hydroxyphenyl) retinamide targets Zika virus (ZIKV) nonstructural protein 5 to inhibit ZIKV infection”, Biochemical an Biophysical Research Communications, 493:1555-1559 (201…
[cited by applicant]
Weisbart, “Antibody-mediated transduction of p53 selectively kills cancer cells”, Int. J. Oncol., 25(6):1867-1873 (2004).
[cited by applicant]
Weisbart, et al., “ Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells”, Cancer Letters, 195(2): 211-219 (2003b).
[cited by applicant]
Weisbart, et al., “A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus”, J Immunol., 144(7): 2653-2658 (1990).
[cited by applicant]
Weisbart, et al., “An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications”, J. Autoimmun., 11(5):539-546 (1998).
[cited by applicant]
Weisbart, et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin Ilb”, Mol Immunol, 39(13):783-789 (2003a).
[cited by applicant]
Weisbart, et al., “DNA-dependent targeting of cell nuclei by a lupus autoantibody”, Sci Rep., 5(12022):1-6 (2015).
[cited by applicant]
Weisbart, et al., “Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells”, J Immunol., 164(11): 6020-6026 (2000).
[cited by applicant]
Wulbrand, et al., “Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation”, PLoS One, 8 (5): e64730 (2013).
[cited by applicant]
Yanase, et al., “Cellular Entry and Nuclear Localization of Anti-DNA Antibodies”, Autoimmune Reactions, 19: 293-304 (1999).
[cited by applicant]
Yanase, et al., “Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1”, J. Clin. Invest., 100(1):25-31 (1997).
[cited by applicant]
Ying-Chyi, et al., “Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions”, Eur J Immunol., 38(11):3178-3190 (2008).
[cited by applicant]
Yu, et al., “Diagnostic criteria for systemic lupus erythematosus: a critical review”, J Autoimmun., 48-49:10-3 (2014).
[cited by applicant]
Zack, et al., “DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus”, J. Immunol., 154(4):1987-94 (1995).
[cited by applicant]
Zack, et al., “Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody”, J Immunol., 157(5): 2082-2088 (1996).
[cited by applicant]
Zack, et al., “Novel structural features of autoantibodies in murine lupus: a possible superantigen binding site?”, Immunology and Cell Biology, 72:513-520 (1994).
[cited by applicant]
Zhan, et al., “Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats”, Stroke: A Journal of Cerebral Circulation, 41(3):538-543 (2010).
[cited by applicant]
Zhu, et al., “Remodeling domain interfaces to enhance heterodimer formation”, Protein Sci., 6(4):781 (1997).
[cited by applicant]
Aagaard et al., “RNAi therapeutics: Principles, prospects and challenges”Advanced Drug Delivery Reviews 59 75-86 (2007).
[cited by applicant]
Blumberg et al., “Unraveling the autoimmune translational research process layer by layer” (Nat.; 18(1): 35-41) (2015).
[cited by applicant]
Bork.“Powers and Pitfalls in Sequences Analysis: The 70% Hurdle.” Genome Research 10:398-400(2000).
[cited by applicant]
Brown, et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody Vh CDR2” Immunol. 156(9):3285-91(1996).
[cited by applicant]
Burgess at al., Possible Dissociation of the Heparin-binding and Mitogenic Activites of Heparin-binding(Acidic Fibroblast) Growth Factor-1 from Its Receptor binding Activities by Site-directed Mutagenesis of a Single Ly…
[cited by applicant]
Clark et al., Discovery and Development of Janus Kinase(KAK) Inhibitors for Inflammatory Diseases J. Med. Chem., 57(12) pp. 5023-5038 (2014).
[cited by applicant]
Greenspan et al., Defining epitopes: It's not as easy as it seems; Nature Biotechology, 17:936-937(1999).
[cited by applicant]
Guido et al., “Virtual Screening and Its Integration with Modern Drugs Design Technologies” Curr Med Chem. 2008 15(1) 34-46(2008).
[cited by applicant]
Kulmanov et al., “DeepGO: predicting protein functions from sequence and interactions using a deep ontology-aware classifer”Bioinformatics, 34(4), 660-668(2018).
[cited by applicant]
Lazar et al., Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol Cell. Biol., 8:1247-1252 (1988).
[cited by applicant]
Ma.“Animal Models of Disease” Modern Drug Discovery 7(6), 30-36 (2004).
[cited by applicant]
McKeague et al., “Challenges and opportunities for small molecule aptamer Development” J Nucleic Acids. 2012:748913 EPub (2012).
[cited by applicant]
Miosge, et al., “Comparison of predicted and actual consequences of missense mutations”Proc Natl Acad Sci USA 112(37) E5 189-98(2015.
[cited by applicant]
Ola et al., “Importin beta: A novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage.” A Journal of Autoimmunity 26 197-207 (2006).
[cited by applicant]
Skolnick et al.,“From Genes to Protein structure and function: novel applications of computational approaches in genomic era” Trends Biotechnol. 18(1): 34-9(2000.
[cited by applicant]
Solderholm et al., ACS Chem Biol. 6, 700-708 (2011).
[cited by applicant]
Steinman et al., “Optimization of current and future therapy for autoimmune diseases” Nat Med 6;18(1) 59-65 (2012).
[cited by applicant]
Takahashi et al., DNA microarray analysis identifies NR4A2 as novel molecule involved in the pathogenesis of Sjogren's syndromeClinical and Experimental Immunology 190: 96-109 (2017).
[cited by applicant]
Torok et al., “Pharmacogenetics of Crohn's disease” Pharmacogenomics 9(7) 881-893(2008).
[cited by applicant]
Vajdos, et al., “Comprehensive functional maps of the antigen-binding site of am amti-ErbB2 antibody obtained with shotgun scanning mutagenesis”, J Mol Biol., 320:415-28 (2002).
[cited by applicant]
Warzocha et al., “Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies” Leukemia and Lymphoma vol. 24 pp. 267-281 (1997).
[cited by applicant]
Crump, Ivermectin: enigmatic multifaceted ‘Wonder’ drug continues to surprise and exceed expectations. 70. 495-505 (2017).
[cited by applicant]
Cited By (1)